Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


CSL could face profit squeeze

Posted 6 August 2021 AM

Investment bank Macquarie Capital has cut both its earnings estimate and target price for CSL shares because of problems the Australian biotech has had in collecting blood plasma.

The company's plasma collection had been significantly affected by the COVID-19 pandemic and, according to the Australian Financial Review, a recent surge in Covid cases in the US coupled with unemployment benefits and a restriction on Mexican citizens from being paid for donations has further reduced stocks.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Melb pharma registers first copy
Long list of generic versions of PBS-listed drugs